Intrathecal long-term gene expression by self-complementary adeno-associated virus type I suitable for chronic pain studies in rats

Molecular Pain

Volumn 2, Issue , 2006, Pages

  Storek, Benjamin ^a   Harder, Nina M ^a   Banck, Michaela S ^a   Wang, Cheng ^a   McCarty, Douglas M ^b   Janssen, William G M ^a   Morrison, John H ^a   Walsh, Christopher E ^a   Beutler, Andreas S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED DNA; ENHANCED GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR; PRIMER DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAUDA EQUINA; CEREBROSPINAL FLUID; CHRONIC PAIN; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA MODIFICATION; FLUORESCENCE ANALYSIS; FOREBRAIN; GENE EXPRESSION; GENE TRANSFER; HYPOTHESIS; LUMBAR PUNCTURE; MALE; MENINX; MICROSCOPY; NERVE ROOT; NOCICEPTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROCESS MODEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; SEROTYPE; SPINAL CORD; TARGET CELL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS PARTICLE; VIRUS RECOMBINANT; WESTERN BLOTTING; ADENO ASSOCIATED VIRUS; ANIMAL; CHRONIC DISEASE; GENE VECTOR; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PAIN;

ANIMALS; BASE SEQUENCE; CHRONIC DISEASE; DEPENDOVIRUS; DNA PRIMERS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; MICROSCOPY, CONFOCAL; PAIN; POLYMERASE CHAIN REACTION; RATS; SPINAL CORD; TRANSGENES;

EID: 33646403729     PISSN: 17448069     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-8069-2-4     Document Type: Article

References (38)

1. Ummenhofer WC, et al.: Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanyl, and sufentanil. Anesthesiology 2000, 92(3):739-53.
2. Yaksh TL, Henry JL: Antinociceptive effects of intrathecally administered human beta-endorphin in the rat and cat. Can J Physiol Pharmacol 1978, 56(5):754-9.
3. Yaksh TL, Rudy TA: Analgesia mediated by a direct spinal action of narcotics. Science 1976, 192(4246):1357-8.
4. Smith TJ, et al.: Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002, 20(19):4040-9.
5. Smith TJ, Coyne PJ: How to use implantable intrathecal drug delivery systems for refractory cancer pain. J Support Oncol 2003, 1(1):73-6.
6. Crul BJ, Delhaas EM: Technical complications during long-term subarachnoid or epidural administration of morphine in terminally ill cancer patients: a review of 140 cases. Reg Anesth 1991, 16(4):209-13.
7. Devulder J, et al.: Spinal analgesia in terminal care: risk versus benefit. J Pain Symptom Manage 1994, 9(2):75-81.
8. Nitescu P, et al.: Complications of intrathecal opioids and bupivacaine in the treatment of "refractory" cancer pain. Clin J Pain 1995, 11(1):45-62.
9. Mannes AJ, et al.: Adenoviral gene transfer to spinal-cord neurons: intrathecal vs. intraparenchymal administration. Brain Res 1998, 793(1-2):1-6.
10. Finegold AA, Mannes AJ, Iadarola MJ: A paracrine paradigm for in vivo gene therapy in the central nervous system: treatment of chronic pain. Hum Gene Ther 1999, 10(7):1251-7.
11. Milligan ED, et al.: Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur J Neurosci 2005, 21(8):2136-48.
12. Milligan ED, et al.: Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol Pain 2005, 1(1):9.
13. Lin CR, et al.: Electroporation for direct spinal gene transfer in rats. Neurosci Lett 2002, 317(1):1-4.
14. Lin CR, et al.: Electroporation-mediated pain-killer gene therapy for mononeuropathic rats. Gene Ther 2002, 9(18):1247-53.
15. Meuli-Simmen C, et al.: Gene expression along the cerebral-spinal axis after regional gene delivery. Hum Gene Ther 1999, 10(16):2689-700.
16. Sloane EM, et al.: Chronic constriction injury induced pathological pain states are controlled long-term via intrathecal administration of a non-viral vector (NVV) encoding the anti-inflammatory cytokine, Interleukin-10 (IL-10). In 2nd joint scientific meeting of the American Pain Society and the Canadian Pain society Vancouver, B.C. Canada: Elsevier; 2004.
17. Carter BJ: Adeno-associated virus vectors in clinical trials. Hum Gene Ther 2005, 16(5):541-50.
18. Xu Y, et al.: Efficiencies of transgene expression in nociceptive neurons through different routes of delivery of adeno-associated viral vectors. Hum Gene Ther 2003, 14(9):897-906.
19. Eaton MJ, et al.: Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord. Gene Ther 2002, 9(20):1387-95.
20. Stilwell JL, Samulski RJ: Adeno-associated virus vectors for therapeutic gene transfer. Biotechniques; 2003, 34(1):148-50. 152, 154 passim
21. Chao H, et al.: Sustained and complete phenotype correction of hemophilia b mice following intramuscular injection of aavl serotype vectors. Mol Ther 2001, 4(3):217-22.
22. Chao H, et al.: Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2000, 2(6):619-23.
23. Davidson BL, et al.: Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA 2000, 97(7):3428-32.
24. McCarty DM, Monahan PE, Samulski RJ: Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 2001, 8(16):1248-54.
25. McCarty DM, et al.: Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003, 10(26):2112-8.
26. Beutler AS, et al.: Retrovirus-mediated expression of an artificial beta- endorphin precursor in primary fibroblasts. J Neurochem 1995, 64(2):475-81.
27. Ishii K, et al.: Attempted gene therapy for intractable pain: dexamethasone-mediated exogenous control of betaendorphin secretion in genetically modified cells and intrathecal transplantation. Exp Neurol 2000, 166(1):90-8.
28. Mulligan RC: The basic science of gene therapy. Science 1993, 260(5110):926-32.
29. Glorioso JC, Fink DJ: Use of HSV vectors to modify the nervous system. Curr Opin Drug Discov Devel 2002, 5(2):289-95.
30. Goss JR, et al.: Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther 2001, 8(7):551-6.
31. Wilson SP, et al.: Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci USA 1999, 96(6):3211-6.
32. Beutler AS, et al.: Intrathecal gene transfer by adeno-associated virus for pain. Curr Opin Mol Ther 2005, 7(5):431-9.
33. Watkins LR, Maier SF: Immune regulation of central nervous system functions: from sickness responses to pathological pain. J Intern Med 2005, 257(2):139-55.
34. Watkins LR, Maier SF: Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2003, 2(12):973-85.
35. Chao H, et al.: Persistent expression of canine factor IX in hemophilia B canines. Gene Ther 1999, 6(10):1695-1704.
36. Walsh CE: Gene therapy progress and prospects: gene therapy for the hemophilias. Gene Ther 2003, 10(12):999-1003.
37. Flotte TR: Immune responses to recombinant adeno-associated virus vectors: putting preclinical findings into perspective. Hum Gene Ther 2004, 15(7):716-7.
38. Malkmus SA, Yaksh TL: Intrathecal catheterization and drug delivery in the rat. Methods Mol Med 2004, 99:109-21.